Sunmax Biotechnology Co., Ltd. (TPEX:4728)
Taiwan
· Delayed Price · Currency is TWD 419.00
+11.00 (2.70%)
May 23, 2025, 1:30 PM CST
Sunmax Biotechnology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 1,945 | 1,818 | 1,689 | 1,400 | 1,036 | 855.85 | Upgrade
|
| Revenue Growth (YoY) | 12.83% | 7.64% | 20.64% | 35.19% | 21.01% | 44.05% | Upgrade
|
| Cost of Revenue | 381.91 | 339.35 | 284.1 | 207.27 | 141.21 | 154.65 | Upgrade
|
| Gross Profit | 1,563 | 1,479 | 1,405 | 1,193 | 894.45 | 701.2 | Upgrade
|
| Selling, General & Admin | 525.75 | 512.52 | 481.35 | 407.22 | 502.21 | 353.73 | Upgrade
|
| Research & Development | 44.02 | 39.18 | 28.74 | 17.97 | 24.63 | 17.53 | Upgrade
|
| Operating Expenses | 569.77 | 551.7 | 510.1 | 424.8 | 527.08 | 368.89 | Upgrade
|
| Operating Income | 992.89 | 926.96 | 894.8 | 768 | 367.37 | 332.31 | Upgrade
|
| Interest Expense | -5.68 | -5.95 | -2.94 | -1.35 | -2.81 | -2.92 | Upgrade
|
| Interest & Investment Income | 11.32 | 11.24 | 13.2 | 7.18 | 3.79 | 8.45 | Upgrade
|
| Currency Exchange Gain (Loss) | 17.12 | 17.12 | 1.95 | 2.43 | -3.03 | 3.98 | Upgrade
|
| Other Non Operating Income (Expenses) | -1.53 | 4.84 | 2.51 | 0.46 | -6.23 | 4.08 | Upgrade
|
| EBT Excluding Unusual Items | 1,014 | 954.22 | 909.52 | 776.71 | 359.1 | 345.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.63 | -0.63 | - | - | - | -8.32 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.49 | -0.49 | -0.13 | 0.46 | -2.1 | 0.17 | Upgrade
|
| Other Unusual Items | 0.18 | 0.18 | - | 0.01 | 0.49 | - | Upgrade
|
| Pretax Income | 1,013 | 953.28 | 909.39 | 777.18 | 357.49 | 337.76 | Upgrade
|
| Income Tax Expense | 286.82 | 273.87 | 283.68 | 243.35 | 111.84 | 99.68 | Upgrade
|
| Earnings From Continuing Operations | 726.36 | 679.41 | 625.71 | 533.83 | 245.64 | 238.08 | Upgrade
|
| Net Income | 726.36 | 679.41 | 625.71 | 533.83 | 245.64 | 238.08 | Upgrade
|
| Net Income to Common | 726.36 | 679.41 | 625.71 | 533.83 | 245.64 | 238.08 | Upgrade
|
| Net Income Growth | 7.79% | 8.58% | 17.21% | 117.32% | 3.18% | 137.02% | Upgrade
|
| Shares Outstanding (Basic) | 54 | 54 | 54 | 54 | 54 | 54 | Upgrade
|
| Shares Outstanding (Diluted) | 55 | 55 | 55 | 55 | 55 | 55 | Upgrade
|
| Shares Change (YoY) | -0.05% | 0.00% | -0.01% | 0.03% | -0.02% | -0.00% | Upgrade
|
| EPS (Basic) | 13.33 | 12.47 | 11.49 | 9.80 | 4.51 | 4.37 | Upgrade
|
| EPS (Diluted) | 13.33 | 12.46 | 11.47 | 9.79 | 4.51 | 4.37 | Upgrade
|
| EPS Growth | 7.93% | 8.63% | 17.16% | 117.07% | 3.20% | 137.50% | Upgrade
|
| Free Cash Flow | 649.91 | 529.07 | 740.9 | 489.99 | -9.74 | 257.11 | Upgrade
|
| Free Cash Flow Per Share | 11.92 | 9.70 | 13.59 | 8.98 | -0.18 | 4.71 | Upgrade
|
| Dividend Per Share | 11.600 | 11.600 | 11.000 | 9.500 | 4.400 | 2.000 | Upgrade
|
| Dividend Growth | 5.46% | 5.46% | 15.79% | 115.91% | 120.00% | 33.33% | Upgrade
|
| Gross Margin | 80.36% | 81.33% | 83.18% | 85.19% | 86.37% | 81.93% | Upgrade
|
| Operating Margin | 51.06% | 50.99% | 52.98% | 54.85% | 35.47% | 38.83% | Upgrade
|
| Profit Margin | 37.35% | 37.37% | 37.05% | 38.13% | 23.72% | 27.82% | Upgrade
|
| Free Cash Flow Margin | 33.42% | 29.10% | 43.87% | 35.00% | -0.94% | 30.04% | Upgrade
|
| EBITDA | 1,062 | 994.7 | 936.47 | 800.67 | 397.3 | 345.86 | Upgrade
|
| EBITDA Margin | 54.61% | 54.71% | 55.45% | 57.19% | 38.36% | 40.41% | Upgrade
|
| D&A For EBITDA | 69.12 | 67.74 | 41.67 | 32.68 | 29.94 | 13.55 | Upgrade
|
| EBIT | 992.89 | 926.96 | 894.8 | 768 | 367.37 | 332.31 | Upgrade
|
| EBIT Margin | 51.06% | 50.99% | 52.98% | 54.85% | 35.47% | 38.83% | Upgrade
|
| Effective Tax Rate | 28.31% | 28.73% | 31.20% | 31.31% | 31.29% | 29.51% | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.